A Phase 2 interventional study of DAOIB in Long COVID, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan — 5 open to participants now, 5 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · Taiwan.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 7 that started in 2023, is the only one in phase 2, and was the 6th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →5 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan are open now. Recruiting first, the newest first:
POCHIWU · Sites in Taiwan
Ages 20–100
National Taiwan University Hospital · Sites in Taiwan
Ages 6–18 · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages up to 18 · Healthy volunteers
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20+ · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 7 started in 2023.
This study's planned enrollment of 40 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 68 across the 11 interventional studies, 415 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 15 has an industry lead sponsor. The 10 most frequent:
Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.
Chang Gung Memorial Hospital has 2 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05764538Chang Gung Memorial HospitalDAOIB for the Treatment of Brain Fog | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life in long-COVID patients with cognitive impairments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: DAOIB
The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24
Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)
Time frame: week 0, 8, 16, 24
Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24
Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24
Time frame: week 8, 16, 24
Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24
The assessment appears to be a suitable instrument for evaluating activities of daily living in early-phase dementia. Its scores range from 0 (worst) to 78 (best)
Time frame: week 0, 8, 16, 24
Change from baseline in Quality of life score at week 8, 16 and 24
Quality of life will be assessed by Medical Outcomes Study Short-Form-36 (SF-36). The SF-36 consists of eight sections: (1) vitality, (2) physical functioning, (3) bodily pain, (4) general health perceptions, (5) physical role functioning, (6) emotional role functioning, (7) social role functioning, and (8) mental health.
Time frame: week 0, 8, 16, 24
Change from baseline of 17-item Hamilton Rating Scale for Depression
Assessment of depressive symptoms. The 17-item Hamilton Rating Scale for Depression will be measured every 8 weeks
Time frame: week 0, 8, 16, 24
Change from baseline of Hamilton Anxiety Rating Scale
Assessment of anxiety symptoms. The Hamilton Anxiety Rating Scale will be measured every 8 weeks
Time frame: week 0, 8, 16, 24
Change from baseline of Perceived Stress Scale
Assessment of stress and anxiety symptoms. The Perceived Stress Scale will be measured every 8 weeks
Time frame: week 0, 8, 16, 24
Change from baseline in the score of a battery of additional cognitive tests
The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (Wechsler Memory Scale, Spatial Span), verbal/nonverbal learning and memory tests (Wechsler Memory Scale, Word Listing)
Time frame: week 0, 8, 16, 24
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 52 months after the start.
Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 52 months is above that.
Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Benzoate
Post-Acute COVID-19 Syndrome →
Chang Gung Memorial Hospital →